# Is Zepbound a Semaglutide? Brand Names vs Molecules By Ruth Calder, Enforcement Editor (https://glpwatchdog.org/authors/ruth-calder) | Published: 2026-08-16 | Updated: 2026-11-01 Canonical page: https://glpwatchdog.org/research/brand-names-vs-molecules > No. Zepbound is tirzepatide, the same molecule as Mounjaro. Nine brand names cover five molecules, and knowing which is which decides your price and your coverage. ## Key points - Wegovy / Ozempic / Rybelsus = semaglutide. Zepbound / Mounjaro = tirzepatide. Saxenda / Victoza = liraglutide. - Coverage follows the LABEL, not the molecule, so which name is on the prescription can decide whether it is paid for. - There is no approved oral tirzepatide. The approved pills are semaglutide (Rybelsus, the Ozempic pill, the Wegovy pill) and orforglipron (Foundayo). - Compounded sellers sell the MOLECULE and quote the BRAND’s trial. The substance is shared, but the evidence does not transfer. No, Zepbound is not a semaglutide. It is **tirzepatide**, the same molecule as Mounjaro. Wegovy and Ozempic are both semaglutide, and both now come as a daily tablet as well as a weekly pen. Rybelsus is semaglutide too. The nine brand names below cover five molecules, and knowing which is which is the difference between reading a price correctly and being sold something on a trial result that was never about it. This is not pedantry. Almost every confusing thing in this market comes back to the gap between a brand and the substance inside it: why two drugs cost the same, why your insurer covers one and not the other, why a compounded seller quotes a number from a trial they were not in. ## The whole map, on one table *Brand names and the molecules inside them, from the current FDA labels[1][2][4]* | Brand | Molecule | Approved for | Form | | --- | --- | --- | --- | | Wegovy | **semaglutide** | Chronic weight management; cardiovascular risk reduction | Weekly injection or daily tablet | | Ozempic | **semaglutide** | Type 2 diabetes, including cardiovascular risk reduction | Weekly injection or daily tablet | | Rybelsus | **semaglutide** | Type 2 diabetes, including cardiovascular risk reduction | Daily tablet | | Zepbound | **tirzepatide** | Chronic weight management; obstructive sleep apnea | Weekly injection | | Mounjaro | **tirzepatide** | Type 2 diabetes, including cardiovascular risk reduction | Weekly injection | | Saxenda | **liraglutide** | Chronic weight management | Daily injection | | Victoza | **liraglutide** | Type 2 diabetes | Daily injection | | Trulicity | **dulaglutide** | Type 2 diabetes | Weekly injection | | Foundayo | **orforglipron** | Chronic weight management | Daily tablet | Every molecule with both a diabetes label and a weight label gets a separate brand name for each. The drug is the same and so is the factory. The box is different, and so, frequently, are the price and the coverage. > **Why they bother.** A drug is approved for an indication, not for a molecule, and the trials, the labeling and the insurance treatment all attach to that. Splitting the brands lets a manufacturer run separate trials, hold separate approvals and price separately into two markets that pay very differently. It is legitimate, and it is why one package of semaglutide carried a list price of $1,027.51 as Ozempic and $1,349.02 as Wegovy in October 2026. Novo has announced that both fall to $675 on January 1, 2027.[9] ## Where this costs you money 1. **Coverage follows the label, not the molecule.** A plan that excludes weight-management drugs may still cover the diabetes-labeled twin when the diagnosis is diabetes. Which name is on the prescription can decide whether it is paid for. 2. **Manufacturer cash ladders differ by brand.** In October 2026 Novo charged the same $349 a month for [Wegovy and Ozempic pens](https://glpwatchdog.org/learn/glp-1-medications/ozempic-vs-wegovy) at most doses, but $399 for Wegovy HD and $499 for Ozempic 2 mg.[5][6] Lilly charged $299 to $699 for the Zepbound KwikPen depending on dose and refill timing, and $499 for Mounjaro at every dose.[7][8] Same molecule, different ladder, so at a high dose the diabetes brand can be the cheaper one. 3. **Trial results attach to a dose, not a name.** Ozempic tops out at 2 mg for diabetes. Wegovy’s usual maintenance dose is 2.4 mg for weight, and the label now allows 7.2 mg for some patients.[1] Quoting weight-loss figures from one at the doses of the other overstates what you should expect. 4. **Compounded sellers sell the molecule.** Nobody is selling you compounded Zepbound. They are selling compounded tirzepatide, a different product with different oversight, and they often quote Zepbound’s trial number next to it. > **That last one is the seam the marketing runs through.** SURMOUNT-1’s 20.9% was measured on tirzepatide manufactured by Eli Lilly under Good Manufacturing Practice, at protocol doses. Nothing compounded from that molecule was in the trial. No compounded version has been reviewed as such, and the concentration of each one is set by whichever pharmacy filled it. The molecule is shared; the evidence is not transferable. So when a listing says compounded semaglutide or tirzepatide, read it as the molecule from a pharmacy, not as the brand. [Mevo Health](https://glpwatchdog.org/reviews/mevo-health), [HealthRX](https://glpwatchdog.org/reviews/healthrx) and [Blue Sky MD](https://glpwatchdog.org/reviews/blue-sky-md) all sell both molecules that way; Blue Sky MD sells them only inside its full medical weight-loss program, with coaching. [Loozy](https://glpwatchdog.org/reviews/loozy) publishes a price for compounded semaglutide only, with tirzepatide offered inside its intake. One seller can sell both the molecule and the brand, so check which line of the menu you are reading. [Tuyo Health](https://glpwatchdog.org/reviews/tuyo-health) sells compounded semaglutide and tirzepatide with no membership fee, and separately sells brand Wegovy and Zepbound on plans that do carry a membership, with its team handling the insurance paperwork. [Found](https://glpwatchdog.org/reviews/found) is set up the other way round: its compounded plans bundle the medication and membership at one price per dose, while brand-name drugs are billed separately from the membership. ## Which of these is a pill? Four brand names, two molecules, and neither is tirzepatide. **Rybelsus** and **Ozempic tablets** are oral semaglutide for type 2 diabetes, sold under one label but in different strengths, and the label says they are not substitutable milligram for milligram.[4] In the US, Ozempic tablets are [replacing Rybelsus](https://glpwatchdog.org/research/is-rybelsus-being-discontinued). The **Wegovy pill** is oral semaglutide for weight management, approved in December 2025, with 25 mg daily as the maintenance dose.[1] All three need a strict fasting window because a peptide barely survives the gut without help. **Foundayo** is orforglipron, approved in April 2026 for weight management. It is a non-peptide small molecule, which is why it does not need the same food rules. There is no oral tirzepatide. If a seller offers you “tirzepatide tablets” or a sublingual version, they are offering a compounded preparation with no approved counterpart and therefore no bioavailability standard to measure it against. Nobody can tell you what fraction of the dose reaches your bloodstream. And whatever you are offered, it is not [a patch](https://glpwatchdog.org/research/do-glp1-patches-work), because a peptide that size does not cross skin. Several sellers in our register list exactly that. [HealthSource](https://glpwatchdog.org/reviews/healthsource) sells compounded tirzepatide as an oral sublingual, and [YourHealthRx](https://glpwatchdog.org/reviews/yourhealthrx) sells compounded semaglutide and tirzepatide as daily dissolving tablets. [He & She MD](https://glpwatchdog.org/reviews/he-and-she-md) lists oral versions of both beside access to brand Ozempic, Zepbound and Wegovy, and [VirtualCare2Go](https://glpwatchdog.org/reviews/virtualcare2go), a [Texas](https://glpwatchdog.org/states/texas)-only practice, sells semaglutide tablets in a monthly package. Whatever the checkout calls it, ask which of the two you are buying: an approved tablet or a compounded preparation. ## Things sold beside these that are not GLP-1s at all Peptide sellers frequently list these next to GLP-1s, which invites the assumption that they belong to the same family. They do not. For the prescription drugs most often mistaken for one, see [which drugs are GLP-1s](https://glpwatchdog.org/research/which-drugs-are-glp1s). - **Tesamorelin (EGRIFTA)** is a growth hormone-releasing factor analog, approved for HIV-associated lipodystrophy, and its label says it is [not indicated for weight loss management](https://glpwatchdog.org/research/tesamorelin-for-weight-loss). - **BPC-157** is not approved for anything, and it is [not on the list](https://glpwatchdog.org/research/bpc-157-what-fda-actually-said) a compounding pharmacy may lawfully use. Under an interim policy dated October 28, 2026, HHS does not plan to pursue 503A pharmacies that compound it under strict conditions, which is not an approval.[10] - **Retatrutide** is a real Lilly drug candidate whose [phase 3 trials](https://glpwatchdog.org/research/retatrutide-what-the-evidence-shows) have begun to report. It is not approved anywhere, and Lilly plans to apply in the first quarter of 2027, whatever is being sold under the name now. - **Sermorelin, ipamorelin and AOD-9604** are growth-hormone-axis peptides, not incretin drugs. They work by a different mechanism and rest on different evidence, and none of them is approved for weight loss; [AOD-9604 was tested for obesity and failed](https://glpwatchdog.org/research/aod-9604-what-the-evidence-shows). ## Common questions ## Frequently asked questions ### Is Zepbound a semaglutide? No. Zepbound is tirzepatide, a dual GLP-1 and GIP agonist. Semaglutide is the molecule in Wegovy, Ozempic and Rybelsus. The two are different drugs from different manufacturers, and tirzepatide produced larger weight loss when they were compared head-to-head. ### Are Zepbound and Mounjaro the same thing? It is the same molecule from the same manufacturer at the same doses, under two names for two approvals. The Zepbound label covers long-term weight management and obstructive sleep apnea; the Mounjaro label covers type 2 diabetes. Which one you can get usually depends on which diagnosis is on the prescription. ### Are Wegovy and Ozempic the same? Both are semaglutide from Novo Nordisk, and both come as a pen or a daily tablet. Wegovy is dosed for weight management, usually at 2.4 mg weekly and up to 7.2 mg for some patients; Ozempic tops out at 2 mg for diabetes. It is the same substance with different target doses, different labels and quite different pricing programs. ### Does tirzepatide come in pill form? Not as an approved product. The approved oral GLP-1 drugs are semaglutide, sold as Ozempic tablets (which are replacing Rybelsus in the US) and the Wegovy pill, and orforglipron, sold as Foundayo. Anything sold as tirzepatide tablets or sublingual drops is a compounded preparation with no approved counterpart, which means there is no established figure for how much of it reaches your bloodstream. ### If a seller offers compounded semaglutide, is that Wegovy? No. A compounding pharmacy made it from the same molecule, but it is not the FDA-approved product. It has not been reviewed as that preparation for safety, effectiveness or manufacturing quality, and the concentration in the vial is set by the pharmacy. The price gap between the two is large, and so is the difference in oversight. ### Which molecule works best? On weight, the one head-to-head trial gave tirzepatide the edge, but that comparison covers weight only. Wegovy carries a cardiovascular indication for people with heart disease and obesity. Tirzepatide gained one in August 2026, but on the Mounjaro label and only for adults with type 2 diabetes; Zepbound has none. Our drug-versus-drug pages set each pair out with what the evidence does and does not cover. ## Take it further Every pairing has its own page with the trial figures, the manufacturer pricing and what the compounded market charges for each molecule. Start with [Wegovy against Zepbound](https://glpwatchdog.org/compare/drugs/wegovy-vs-zepbound) or [Mounjaro against Zepbound](https://glpwatchdog.org/compare/drugs/mounjaro-vs-zepbound), and [the glossary](https://glpwatchdog.org/glossary) covers the vocabulary sellers use around all of it. ## References 1. U.S. National Library of Medicine WEGOVY, OZEMPIC and RYBELSUS (semaglutide) — prescribing information. DailyMed. 2026. https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=semaglutide 2. U.S. National Library of Medicine ZEPBOUND and MOUNJARO (tirzepatide) — prescribing information. DailyMed. 2026. https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=tirzepatide 3. Theratechnologies Inc. EGRIFTA WR (tesamorelin) — prescribing information, Limitations of Use. DailyMed. 2026. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=839334d3-8c1d-4c26-9036-2ab524a6ea75 4. Novo Nordisk Pharmaceutical Industries, LP RYBELSUS and OZEMPIC (oral semaglutide) tablets — prescribing information. DailyMed. 2026. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=27f15fac-7d98-4114-a2ec-92494a91da98 5. Novo Nordisk Wegovy® Savings Offer — self-pay pricing for the Wegovy pill, pen and Wegovy HD. novocare.com. 2026. https://www.novocare.com/obesity/products/wegovy/savings-offer.html 6. Novo Nordisk Ozempic® Savings Offer — self-pay pricing for the Ozempic pen and pill. novocare.com. 2026. https://www.novocare.com/diabetes/products/ozempic/savings-offer.html 7. Eli Lilly and Company Zepbound® — LillyDirect self-pay pricing. lilly.com, LillyDirect. 2026. https://www.lilly.com/lillydirect/zepbound 8. Eli Lilly and Company Mounjaro® — LillyDirect self-pay pricing. lilly.com, LillyDirect. 2026. https://www.lilly.com/lillydirect/mounjaro 9. Novo Nordisk Novo Nordisk announces significant reduction in US list price for Wegovy®, Ozempic®, and Rybelsus® (semaglutide medicines), building on continued efforts to expand access. PR Newswire, February 24, 2026. 2026. https://www.prnewswire.com/news-releases/novo-nordisk-announces-significant-reduction-in-us-list-price-for-wegovy-ozempic-and-rybelsus-semaglutide-medicines-building-on-continued-efforts-to-expand-access-302695705.html 10. U.S. Department of Health and Human Services HHS Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances (with Appendices A and B), announced October 28, 2026. HHS. 2026. https://www.hhs.gov/sites/default/files/hhs-503a-peptide-enforcement-discretion-policy-appendix-b.pdf --- Cite as: GLP Watchdog, Ruth Calder, "Is Zepbound a Semaglutide? Brand Names vs Molecules", published 2026-08-16, updated 2026-11-01. https://glpwatchdog.org/research/brand-names-vs-molecules Canonical HTML page: https://glpwatchdog.org/research/brand-names-vs-molecules Medical disclaimer: Nothing here is medical advice. We report on this subject; we do not treat anyone. Whether to begin a medication, supplement, or treatment, whether to adjust it, and whether to stop are questions for a clinician licensed to answer them, who knows your history.